Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | METAP2 | P50579 | 3/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35210889 | 0.76 | RXRA (0.36) | RXRARXRBRXRGTRPA1METAP2 | |
| SCHEMBL35211095 | 0.75 | TRPA1 (0.35) | MAPK1RXRARXRBRXRGTRPA1 | |
| SCHEMBL35211775 | 0.75 | METAP2 (0.39) | RXRARXRBRXRGTRPA1METAP2 | |
| SCHEMBL35211500 | 0.75 | METAP2 (0.39) | RXRARXRBRXRGTRPA1METAP2 | |
| SCHEMBL17846441 | 0.75 | MAPK1 (0.41) | MAPK1RXRARXRBRXRG | |
| SCHEMBL35211499 | 0.72 | TRPA1 (0.37) | RXRARXRBRXRGTRPA1METAP2 | |
| SCHEMBL35211066 | 0.71 | NPSR1 (0.41) | RXRARXRBRXRGCD38ALDH1A1 | |
| SCHEMBL30911436 | 0.71 | TRPA1 (0.36) | RXRARXRBRXRGTRPA1METAP2 | |
| SCHEMBL30911387 | 0.71 | NT5E (0.34) | — | |
| SCHEMBL30911399 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | CCR1, CCR6, CCRL2 | MAPK1 1031/4885RXRA 324/4885RXRB 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.